Regentis Biomaterials' GelrinC Cartilage Repair Technology Shows Potential in U.S. Market

Regentis Biomaterials (NYSE American: RGNT) is developing a cell-free, off-the-shelf hydrogel implant called GelrinC that is designed to regenerate knee cartilage. The implant gradually resorbs over approximately six to nine months as new tissue fills the treated area. According to the company, its Pilot/Phase II study demonstrated 100% greater pain improvement compared with traditional microfracture treatment, and 24-month follow-up results showed a mean MOCART score of 88.8 out of 100, an MRI-based measure of cartilage repair quality.

GelrinC has received a CE mark in Europe, providing a pathway for commercialization in that market, while Regentis advances its pivotal Phase III clinical study in the United States and prepares for the FDA’s Premarket Approval process. The company is also working to complete enrollment in its U.S. study and expand commercialization efforts. This matters because GelrinC aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. where no off-the-shelf treatment is available. For Texas, a state with a growing healthcare and life sciences sector, such innovations could spur economic activity and improve patient outcomes. The technology’s potential to deliver lasting improvements in pain and mobility aligns with broader trends in orthopedic medicine toward durable, long-term treatment outcomes.

Regentis Biomaterials is a regenerative medicine company dedicated to developing innovative tissue repair solutions. Its Gelrin platform technology is based on synchronized, degradable hydrogel implants that regenerate damaged or diseased tissue, including inflamed cartilage and bone. The company’s efforts are featured in a recent article, which can be viewed at https://ibn.fm/cTSlo. The latest news and updates relating to RGNT are available in the company’s newsroom at https//ibn.fm/RGNT.

The dissemination of this content is part of a paid investor awareness and marketing engagement, executed through MissionIR, a specialized communications platform focused on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. MissionIR is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries, as well as article and editorial syndication to 5,000+ outlets, enhanced press release enhancement to ensure maximum impact, social media distribution via IBN to millions of social media followers, and a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public.

For more information, please visit www.MissionIR.com. Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer.